906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens

Racial disparities in health outcomes of patients with diffuse large B cell lymphoma using real world data

Social determinants of health and long term survival in chronic lymphocytic leukemia small lymphocytic lymphoma A population based analysis of 118 667 patients

Multi centre real world outcome of patients with Richter transformation receiving CD19 directed commercial CAR T cell therapy in Australia

Comparable outcomes after autologous hematopoietic cell transplantation in T cell lymphoma regardless of pre transplant response A key finding in resource limited countries

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia A real world multicenter analysis from Latin America

Cardiovascular outcomes in CLL patients receiving GLP 1 agonists and  BTK inhibitors A global propensity matched study

Impact of age on outcomes of CAR T cell therapy in multiple myeloma DLBCL and follicular lymphoma A real world multi center propensity matched analysis

Preliminary data on epcoritamab and glofitamab as bridging therapy prior to CAR T cell treatment in Relapsed Refractory large B cell lymphoma

Limited stage Mantle Cell Lymphoma Real world outcomes according to nodal vs extranodal presentation

Outcomes during BTKi treatment for chronic lymphocytic leukemia Insights from remote therapeutic monitoring

Real world efficacy outcomes of epcoritamab and glofitamab in Relapsed Refractory aggressive B cell lymphoma A single center cohort emphasizing trial ineligible populations

Outcome disparities among survivors of hematologic malignancies diagnosed in childhood

Variances in patient reported experiences with shared decision making by biological sex in patients with diffuse large B cell lymphoma DLBCL – an analysis from the lymphoma coalition 2024 global patient survey on lymphomas and CLL

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life A lysa study from descar T and realysa registries

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real world practice Unmet needs treatment patterns and age disparities in the United States

Outcomes of autologous stem cell transplantation using busulfan melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B cell lymphoma

Analysis of lymphoma subtypes involved sites and treatment outcomes in primary gastrointestinal B cell lymphomas A subset analysis within the PELÉ study of brazilian centers

Real world comparative outcomes of pola R CHP versus R CHOP in patients with diffuse large B cell lymphoma

Real world comparative outcomes of CAR T cell therapy versus bispecific T cell engagers in patients with relapsed acute lymphoblastic leukemia

Naive CD4 at apheresis and disease control at infusion are associated with improved efficacy in second line CAR T cells

Incidence and risk factors of chronic kidney disease CKD in lymphoma survivors

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma A 23 year real world experience

Effectiveness of remote patient monitoring in enabling outpatient step up dosing for bispecifics at a large academic cancer center in the USA

Beyond remission Sexual health and quality of life in survivors of acute leukemia

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide doxorubicin and prednisone in untreated diffuse large B cell lymphoma A real world study from China

Addressing psychological burden in patients newly diagnosed with lymphoma or myeloma Patient perspectives on potential interventions

Impact of the number of bridging therapy lines on outcomes after axi cel in LBCL A lysa study from the descar T registry

CAR T cell therapy versus autologous HSCT in patients with large B cell lymphoma in complete remission An analysis from the EBMT lymphoma working party

Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia ALL trial AALL1731 A report from the Children s oncology group

Predictive performance of the LEO comorbidity index in patients aged 80 years with large B cell lymphoma

Efficacy of CAR T cell therapy in chronic lymphocytic leukemia A meta analysis

Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next generation Bruton tyrosine kinase BTK inhibitors A meta analysis of randomized controlled trials

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed refractory lymphoma in the modern era

Therapeutic ANC attainment during maintenance chemotherapy for pediatric acute lymphoblastic leukemia

Evolving patient reported value of treatment attributes in follicular lymphoma Insights from the lymphoma coalition 2024 global patient survey on lymphomas and CLL

Toxicity efficacy and clinical management of bispecific antibodies in routine clinical practice A real world geltamo study in B cell lymphoma

Pediatric inspired regimens for ALL are not associated with improved overall survival in US hispanic adult patients

Effect of immunoglobulin replacement therapy on the incidence of severe infections in patients with chronic lymphocytic leukemia

First worldwide real life data on fixed duration ibrutinib venetoclax treatment for previously untreated CLL SLL patients Updated interim analysis of Spain´s LI VE observational study

Optimizing the treatment of secondary central nervous system lymphoma SCNSL with intensive systemic and cns targeted chemoimmunotherapy followed by autologous stem cell transplant ASCT A retrospective single center analysis of a modified ferreri protocol

Influence of HIV status age and ethnicity on survival in patients with burkitt lymphoma BL and diffuse large B cell lymphoma DLBCL A real world nationwide database study

Real world treatment patterns patient characteristics and outcomes of cbtki based therapies amongst a contemporary cohort of patients with R R MCL in the United States

Real world incidence of bleeding events in patients with chronic lymphocytic leukemia treated with acalabrutinib obinutuzumab and requiring direct oral anticoagulation

Real world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL SLL from 2020 to 2024

Barriers to receiving CAR T cell treatment among patients with non Hodgkin lymphoma who were deemed eligible for CAR T cell therapy

Mediators of racial and ethnic inequities in access to front line therapies for chronic lymphocytic leukemia in the United States A real world evidence study

Multiple medication use is associated with increased lymphoma risk in autoimmune diseases Analysis from the life study

Impact of statin use on outcomes in chronic lymphocytic leukemia patients receiving ibrutinib therapy A real world study

Mortality outcomes compared to the general population among long term Hodgkin lymphoma survivors A population based analysis

Patient characteristics toxicity and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia A rocca analysis

Socio economic deprivation in paediatric patients with B cell acute lymphoblastic leukaemia A possible modifiable risk factor based on the real world data from a retrospective survival analysis from the national registry in England

Safety and efficacy of implanted port use for CAR T cells infusion in large B cell lymphoma

Clinical characteristics and treatment patterns of elderly patients living with Mantle Cell Lymphoma

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma A retrospective multicenter international study

Infections in patients with aggressive B cell lymphomas treated with CD3xCD20 bispecific antibodies

Impact of bridging therapies prior to CAR T cell therapy for large B cell lymphoma Real world analysis from the cell therapy consortium

Social support and barriers to medication adherence among adolescents and young adults with leukemia and lymphoma

Real world characteristics treatment patterns and outcomes of patients with mantle cell lymphoma MCL after receiving covalent bruton tyrosine kinase inhibitors cBTKi in China